

A probabilistic perspective on modelling disease progression (with some optimal transport)

Sussex Maths seminar 20/03/25



Our research: bridging computer and life sciences





Our research: bridging computer and life sciences





Background: PhD in particle physics





$$n(C_i^{data}) = \frac{1}{\epsilon_i} \sum_j P(T_i^{MC} \mid R_j^{MC}) n(R_j^{data})$$

• Real data are dependent on the detector used to measure them

Bring data back to their natural state by applying hypothesis-driven corrections derived from simulation



Postdoc 1: Biophysical modelling





The Chemical Basis of Morphogenesis

A. M. Turing

Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, Vol. 237, No. 641. (Aug. 14, 1952), pp. 37-72.



Computational Modeling

Postdoc 1: Biophysical modelling





Postdoc 2 - present: latent variable modelling of dementia



Build latent variable models (LVMs) that can leverage multi-modal data to characterise and predict progression



The big idea: LVM in neuro-degeneration and development

Build latent variable models (LVMs) that can leverage multi-modal data to characterise and predict progression



2

UNIVERSITY OF SUSSEX

The big idea: ML in neuro-degeneration and development





2

High level: disease progression modelling



http://adni.loni.usc.edu/study-design/#background-container

A picture of how components of a disease progresses over time

UNIVERSITY OF SUSSEX

High level: disease progression modelling



http://adni.loni.usc.edu/study-design/#background-container

A picture of how components of a disease progresses over time

UNIVERSITY OF SUSSEX **Phenomenological** – model disease progression in terms of observable changes in markers

e.g., how does the brain change over the course of Alzheimer's?

Mechanistic – model disease progression in terms of underlying mechanisms

e.g., why does the brain change over the course of Alzheimer's?

Low level: disease progression modelling



• Undirected graphical models (a.k.a. Markov networks)

- Directed graphical models (a.k.a. Bayesian networks)
 - Directed acyclic graph (DAG)



• Directed cyclic graph



Low level: disease progression modelling





- Circles: random variables.
- Blue boxes: "plates", signifies that the contents of the box should be repeated number of times in bottom corner.
- Bullet: variables that are not treated as uncertain.

Data: neuroimaging in humans





Typically use magnetic resonance imaging (MRI) data of various types as inputs to models

UNIVERSITY OF SUSSEX

EBM describes disease progression as a sequence of abnormality events

Events represent the change of a biomarker from a healthy to abnormal state

Learns from cross-sectional data of any type (imaging, clinical, biofluid...)





Simple example: 2 event measures

More patients have greater abnormality in Event 2 than Event 1

 \rightarrow Event 2 measurably abnormal before Event 1

Fonteijn et al. NeuroImage (2012) DOI: 10.1016/j.neuroimage.2012.01.062



More formally: EBM is a generative model of observed data from a hidden sequence



• The EBM needs likelihood distributions for healthy and abnormal individuals

\rightarrow Learn directly from data

Fonteijn et al. NeuroImage (2012) DOI: 10.1016/j.neuroimage.2012.01.062







Brain 2014: 137; 2564-2577







A. L. Young et

Brain 2014: 137; 2564–2577



Continuous time hidden Markov model (CTHMM)



What's a Continuous Time Hidden Markov Model (CTHMM)?

Markov Model: a stochastic description of a sequence of observable events, where the probability of each event depends only on the previous state (ie. the probability is *conditional* on the previous state; cf. Poisson process)



Andrey Andreyevich Markov (14th June 1856 – 20th July 1922)

Continuous time hidden Markov model (CTHMM)



CTHMMs can be used to estimate state durations

Problem with Event-Based Model (EBM) - no time between events

Realised EBM is essentially a state-space model

 \rightarrow Reformulate EBM as a special CTHMM: Temporal EBM (TEBM)



$$P(Y|\theta, S) = \prod_{j=1}^{J} \left[\sum_{k=0}^{N} P(k_{j,t=0}) \prod_{t=1}^{T_j} P(k_{j,t}|k_{j,t-1}) \prod_{t=0}^{T_j} \prod_{i=1}^{k_{j,t}} P(Y_{i,j,t}|k_{j,t}, \theta_i^p, S) \prod_{i=k_{j,t}+1}^{I} P(Y_{i,j,t}|k_{j,t}, \theta_i^c, S) \right]$$

Temporal Event-Based Model: provenance



• Guided by this 2014 paper on a continuous-time hidden Markov disease progression model

Unsupervised Learning of Disease Progression Models



• Found this 2007 paper deriving a variable-interval continuous-time hidden Markov model

Generator Estimation of Markov Jump Processes based on

incomplete observations non-equidistant in time*

Philipp Metzner, Illia Horenko, Christof Schütte Institute of Mathematics II, Free University Berlin, Arnimallee 2-6, D-14195 Berlin, Germany

• Complemented by various algorithmic implementations in this 2016 paper

Efficient Learning of Continuous-Time Hidden Markov Models for Disease Progression

Yu-Ying Liu, Shuang Li, Fuxin Li, Le Song, and James M. Rehg

• Can calculate Q(t) using eigendecomposition (fast, requires Q diagonalisable) or directly using Padé method for matrix exponential (slow)



The TEBM is a generative model of observations (e.g., biomarkers) conditional on latent variables (e.g., disease states)

(2021). To formulate the TEBM, we make three main assumptions: i) monotonic biomarker dynamics at the group level; ii) a consistent event sequence across the whole population; and iii) Markov stage transitions at the individual level. We can write the TEBM joint distribution as a hierarchical Bayesian model using the chain rule:

$$P(S,\Theta_i,k_{j,t},Y_{i,j,t}) = P(S,\Theta_i) \cdot P(Y_{i,j,t},k_{j,t}|\Theta_i,S)$$

= $P(S) \cdot P(\Theta_i) \cdot P(k_{j,t}|S,\pi,Q) \cdot P(Y_{i,j,t}|k_{j,t},\theta_i,S).$ (1)

Example: the Temporal Event-Based Model (TEBM)



The TEBM is a generative model of observations (e.g., biomarkers) conditional on latent variables (e.g., disease states)



Wijeratne et al. Imaging Neuroscience 2023

Application: learning Alzheimer's disease timeline



UNIVERSITY OF SUSSEX

Application: learning Alzheimer's disease timeline



UNIVERSITY OF SUSSEX

Optimal transport





Find the optimal mapping **P** that minimises the cost of transporting probability distribution **a** to **b**

Idea: optimal transport for disease trajectory modelling





Transport people to their optimal (latent) stage along an event-based disease trajectory

Variational event-based model: key idea



$$\mathcal{B}_{N} = \left\{ X: \qquad X_{m,n} \ge 0 \qquad \forall m, n \in 1, \dots, N; \right.$$
$$\sum_{n=1}^{N} X_{m,n} = 1 \qquad \forall m \in 1, \dots, N;$$
$$\sum_{m=1}^{N} X_{m,n} = 1 \qquad \forall n \in 1, \dots, N \right\}.$$

These linear row- and column-normalization constraints restrict \mathcal{B}_N to a $(N-1)^2$ dimensional subset of $\mathbb{R}^{N \times N}$.

Reframe the discrete sequence s as a permutation matrix S belonging to the Birkhoff polytope

Aside: Birkhoff polytopes



What's a Birkhoff polytope?

"The Birkhoff polytope, B, is the convex polytope in R^N (where N = n^2) whose points are the doubly stochastic matrices, X, i.e., the $n \times n$ matrices whose entries are non-negative real numbers and whose rows and columns each add up to 1."

 \rightarrow Maps permutation matrices, X, to geometric objects, B

 \rightarrow The top vertex in Figure 2.1 would have a permutation matrix like:

|1, 0, 0| |0, 1, 0| = X |0, 0, 1| https://en.wikipedia.org/wiki/Birkhoff polytope

Paffenholz, 2013. arXiv:1304.3948

Figure 2.2. The wedge over a vertex of a pentagon.

Reframe the discrete sequence s as a permutation matrix S belonging to the Birkhoff polytope

19

UNIVERSITY

OF SUSSEX

Variational event-based model





Input "snapshots" (single observations) from different individuals

Variational event-based model





Model likelihood specified by distributions "normality" and "abnormality"

Variational event-based model





Learn optimal permutation of hidden events and corresponding event sequence

Variational event-based model: key ingredients



$$K(X/\tau) = \underset{S \in \mathcal{B}_{\mathcal{N}}}{\operatorname{argmax}} \langle S, X \rangle_{F} + \tau H(S).$$
Entropy-regularised optimal transport problem
$$M(X) = \begin{bmatrix} e_{s(0)} \\ \vdots \\ e_{s(N)} \end{bmatrix} = \underset{\tau \to 0}{\lim} K(X/\tau).$$
Hard permutation from Sinkhorn-Knopp operator
$$Mena et al, ICLR$$

$$G(X, \tau) \sim K((X + \epsilon)/\tau).$$
 Gumbel-Sinkhorn distribution
arXiv.1802.08665

$$\begin{split} \log P(Y) &\geq \mathcal{L}(\phi; \theta) = \mathbb{E}_{q_{\phi}(Z|Y)}[\log P_{\theta}(Y|Z) - \mathrm{KL}(q_{\phi}(Z|Y) \| P(Z))] \\ &= \mathbb{E}_{q_{\phi}(Z|Y)}[\log P_{\theta}(Y|Z) - \mathrm{KL}(G_{\phi}(X, \tau) \| G(X = 0, \tau_{\mathrm{prior}}))]. \end{split}$$

Enable differentiability by parametrising prior & posterior using Gumbel-Sinkhorn distribution

Fast inference





>1000 x faster than baselines, which use maximum likelihood

Wijeratne & Alexander, NeurIPS 2024, doi: arXiv:2410.14388

Robust to noise



UNIVERSITY

Real data: pixel-level atrophy using tensor-based morphometry data



Use ADNI dataset "TBM Jacobian Maps MDT-SC"

Cross-sectional TBM maps from 816 individuals (299 controls, 399 mild cognitive impairment, 188 AD)



Figure 6.4: This figure illustrates the volume changes estimated by warping together the images shown in Figure 6.3. The relative volumes are the Jacobian determinants of the deformation field. Smaller determinants are obtained when a region of the template maps to a smaller region in the source image. In this example, they represent regions that have expanded between the early and late scans. Regions where there are no measurable volume changes have Jacobian determinants with a value of one.

https://www.fil.ion.ucl.ac.uk/spm/doc/books/hbf2/pdfs/ Ch6.pdf

*Jacobian Map == Deformation tensor

7

Pixel-level progression Alzheimer's disease (AD)





New insights into tissue-level AD progression





New insights into tissue-level AD progression

Pixel-level progression Alzheimer's disease (AD)





New insights into tissue-level AD progression

Pixel-level progression Alzheimer's disease (AD)









Figure 1: **Top Image:** MRI scans of an Alzheimer's patient showing yearly progression, highlighting increased hippocampal atrophy, enlarged ventricles, and widening cortical sulci. **Middle Image:** Annual increase in toxic protein concentration, starting from the brain stem. **Bottom Image:** Simulated annual atrophy patterns, correlating activation time and toxic protein concentration. <u>Weickenmeier, J., Kuhl, E., & Goriely, A. (2018)</u>. <u>Multiphysics of prionlike diseases:</u> Progression and atrophy. Physical review letters, 121 (15), 158101. (https://creativecommons.org/licenses/by/4.0/)



BrainPhys

Challenges in studying mechanisms of neurodegeneration

- → Incomplete knowledge of disease biology
- → Scarcity of longitudinal imaging data

Limitations of conventional deep learning

- → Lack interpretability (act as black boxes)
- → Demand large datasets

Physics informed machine learning combines data-driven methods with physical constraints to **improve interpretability**















Detecting model mis-specification





Detecting model mis-specification



BrainPhys

True t6.0

Predicted t6.0

Residual t6.0

20

X



True t24.0

Predicted t24.0

Residual t24.0

20

40



Predicted t24.0

Residual t24.0

Predicted t36.0

Residual t36.0

Predicted t60.0

Residual t60.0

Predicted t6.0

Residual t6.0

Predicted t18.0

Residual t18.0

Predicted

Residua

0.05

-0.0

Count



1000

800

600

400

200

0

-0.5

+

0

Error

0.5

Summary and next steps



- Probabilistic models can be used to learn hidden information in diseases
- Optimal transport formulation offers many benefits over standard maximum likelihood approaches
- Physics-guided/integrated/informed... machine learning gives flexibility
 - But... identifiability, validation (ground truth?), assumptions, ...

Many interesting theoretical avenues...

Summary and next steps



- Probabilistic models can be used to learn hidden information in diseases
- Optimal transport formulation offers many benefits over standard maximum likelihood approaches
- Physics-guided/integrated/informed... machine learning gives flexibility
 - But... identifiability, validation (ground truth?), assumptions, ...

Many interesting theoretical avenues...

Just need to pick the optimal route!



